A New Jersey federal court awarded the drug manufacturer Sandoz more than $70 million in its lawsuit against United ...

CFO James Edgemond sold 7,800 shares of the business’s stock in a transaction dated Monday, October 28th. The shares were ...

Pallas Capital Advisors LLC raised its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 62.5% during the ...

United Therapeutics (UTHR) came out with quarterly earnings of $6.39 per share, beating the Zacks Consensus Estimate of $6.18 per share. This compares to earnings of $5.38 per share a year ago.

United Therapeutics’ UTHR third-quarter 2024 earnings of $6.39 per share beat the Zacks Consensus Estimate of $6.18. Earnings rose 19% year over year on the back of higher product sales.

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, ...

United Therapeutics Corp showcases robust revenue growth and solid operating income in its latest SEC 10-Q filing. Strengths rooted in innovative PAH therapies and a strong financial position set UTHR ...

High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...